Anxiety and Fear, Pain
Conditions
Keywords
Aromatherapy, Port-a-Cath, Pediatric
Brief summary
The purpose of this study is to determine if the use of aromatherapy impacts patient anxiety and pain scores surrounding port access in pediatric oncology patients between the ages of 4 years and 18 years.
Detailed description
Specific aims include the following: Aim 1: To compare pre and post port access anxiety scores for both control and intervention groups. Aim 2: To assess pre and post port pain scores surrounding port access for both control and intervention groups. Aim 3: To compare pain and anxiety scores between age groups. The overall goal of this pilot study is to identify if aromatherapy, using non-topical, STILL QuickTAB Medipack blended scent aromatherapy, manufactured by Soothing Scents, is effective as a valid non-pharmacologic supplementation in reducing anxiety and pain scores during port access in pediatric oncology patients.
Interventions
OTHERSTILL QuickTAB Medipack blended scent aromatherapy, manufactured by Soothing Scents
A resealable quick-tab dispenser with the 'therapeutic inhaled essential oils' lavender, bergamot, sweet orange, and ylang ylang.
Sponsors
Stanford University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
4 Years to 18 Years
Healthy volunteers
No
Inclusion criteria
1. Children between 4 years and 18 years 2. Scheduled for port access with or without lab draw 3. Oncology, neuro-oncology, and stem cell transplant patients
Exclusion criteria
1. has asthma, reactive airway disease, or allergies to any of the ingredients we are using in the aromatherapy study (lavender, bergamot, sweet orange, and ylang ylang) 2. currently uses aromatherapy for port accesses or other painful procedures (does not apply to patients using aromatherapy, such as peppermint oil, for nausea) 3. has a cognitive impairment that prevents them from being able to provide anxiety or pain scores 4. does not wish to participate in the study
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Effect of aromatherapy on post patient anxiety scores | 5 minutes | Comparison of pre and post patient anxiety scores for both control and intervention groups using the Visual Facial Anxiety Scale with corresponding values ranging from 0-10. 0 indicates no anxiety and 10 indicates the highest level of anxiety. Anxiety score will be measured by using the Visual Facial Anxiety Scale (VFAS) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Effect of aromatherapy on post patient port pain scores | up to 7 minutes | Comparison of pre and post patient pain scale for both control and intervention groups using the 0-10 scale or the Wong-Baker FACES Pain Rating Scale, according to patient preference and age appropriate rating. The Wong-Baker FACES Pain Rating Scale has corresponding faces for numerical rankings of 0-10. For both pain scales, 0 indicates no pain and 10 indicates the worst pain. |
Other
| Measure | Time frame | Description |
|---|---|---|
| Aromatherapy effect according to age | up to 7 minutes | To compare pre and post pain and anxiety scores between the three age groups. The Visual Facial Anxiety Scale will be used to score patient anxiety, with faces corresponding to numerical ratings of 0-10. 0 corresponds with no anxiety and 10 corresponds with the highest level of anxiety. Pain will be scored using the 0-10 Numerical Rating Scale or the Wong-Baker FACES Pain Rating Scale, according to patient preference and age. For both scales, 0 corresponds with no pain and 10 corresponds with the highest pain. |
Countries
United States
Outcome results
None listed